CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Survival after cardiac arrest - Freiburg cardiovascular surgeons develop new technique
(University of Freiburg) German researchers have developed a novel therapeutic approach for resuscitation after cardiac arrest that allows much higher success rates than before - often without neurological complications / Study in Nature Reviews Neuroscience summarizes decisive factors / New „ heart-lung machine " makes clinical implementation possible. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

RNA modification may protect against liver disease, explain liver fat differences between sexes
FINDINGSA chemical modification that occurs in some RNA molecules as they carry genetic instructions from DNA to cells ’ protein-making machinery may offer protection against non-alcoholic fatty liver, a condition that results from a build-up of fat in the liver and can lead to advanced liver disease, according to a new study by UCLA researchers.The study, conducted in mice, also suggests that this modification — known as m6A, in which a methyl group attaches to an RNA chain — may occurat a different ratein femalesthan it does inmales, potentially explaining why females tend to have higher fat content in ...
Source: UCLA Newsroom: Health Sciences - July 19, 2021 Category: Universities & Medical Training Source Type: news

Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub
MELBOURNE, Australia, July 15, 2021 -- Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product developmen...
Source: Johnson and Johnson - July 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Blood Management for Cardiothoracic Surgery: Guidelines Update Blood Management for Cardiothoracic Surgery: Guidelines Update
The Society of Thoracic Surgeons'document, created with multidisciplinary collaboration, includes 23 new or updated recommendations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 7, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Deep learning plus CT helps predict abdominal surgery outcomes
A deep-learning model used with preoperative CT helps predict the complexit...Read more on AuntMinnie.comRelated Reading: Algorithm provides accurate segmentation of pancreas on CT CT, ultrasound provide chance for fatty liver disease screening AI abdominal fat analysis assesses cardiovascular risk AI can opportunistically screen for metabolic syndrome AI plus CT improves liver steatosis assessment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2021 Category: Radiology Source Type: news

Guideline Updated for Blood Management During Heart Surgery
WEDNESDAY, June 30, 2021 -- In a clinical practice guideline update, published online June 30 in the Annals of Thoracic Surgery, recommendations are presented for patient blood management during cardiothoracic surgery. In collaboration with the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bariatric Surgery Leads to Better CV Function in Pregnancy Bariatric Surgery Leads to Better CV Function in Pregnancy
The cardiovascular adaptation of pregnant women after bariatric surgery suggests better hemodynamic function through lower blood pressure, heart rate, and cardiac output, new data show.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 23, 2021 Category: Cardiology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Bariatric Surgery's Cardiovascular Benefit Extends to 7 Years Bariatric Surgery's Cardiovascular Benefit Extends to 7 Years
Patients with obesity who had bariatric surgery had a lower risk of having a major adverse cardiovascular event (MACE) or dying from all causes during a median 7-year follow-up, compared with similar patients who did not undergo surgery.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 22, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Ethicon Expands Advanced Biopolar Energy Portfolio With Launch Of Enseal X1 Curved Jaw Tissue Sealer
CINCINNATI, OH – June 21, 2021 -- Ethicon*, part of the Johnson & Johnson Medical Devices Companies,** today announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency[1] and provided stronger sealing[2] and better access to more tissue than LigaSure™ Maryland.[3] The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures. The ENSEAL X1 Curved Jaw is the first of several new advanced laparoscopic bipolar devices the company plans to launch in the coming months as it expands its extensive ener...
Source: Johnson and Johnson - June 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Women Present With More Advanced Acute Aortic Dissection
MONDAY, June 14, 2021 -- Women with acute aortic dissection are older and have more advanced disease at presentation than men, according to a study published online June 1 in The Annals of Thoracic Surgery. Lauren V. Huckaby, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

WVU Health System adds top pediatric heart expert to lead new center
WVU Health System announced Friday it had hired a pediatric cardiothoracic physician from Children ’s Hospital of Philadelphia to lead its new WVU Medicine Children’s Heart Center. Dr. Christopher E. Mascio will become executive director of the children’s heart center and division chief of pediatric cardiothoracic surgery in the WVU Medicine Department of Cardiovascular and Thoracic Surger y. Mascio is associate clinical chief of the Division of Pediatric Cardiothoracic Surgery and a Cardiac… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 21, 2021 Category: Biotechnology Authors: Paul J. Gough Source Type: news

EPA Facing More Litigation on Legacy Asbestos
The Asbestos Disease Awareness Organization delivered on an earlier notice of intent to sue by filing an official complaint against the U.S. Environmental Protection Agency over its ongoing risk evaluation of asbestos. ADAO, a leading nonprofit aimed at preventing asbestos exposure, was joined by five other organizations and several public health experts in asking the court to set a deadline for the EPA to complete its work. The lawsuit was filed May 18 in the U.S. Northern District of California Court in San Francisco. The notice of intent to sue  was delivered in January. Thoracic surgeon Dr. Raja Flores of Mo...
Source: Asbestos and Mesothelioma News - May 20, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada. Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos. “This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothel...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Pulmonary endarterectomy achieves excellent results for patients with segmental CTEPH
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, found that patients treated surgically for segmental Chronic Thromboembolic Pulmonary Hypertension (CTEPH) had excellent outcomes with the vast majority doing very well in the long term without any additional treatment other than surgery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2021 Category: International Medicine & Public Health Source Type: news

Study finds heart transplantation using donation after cardiac death with NRP
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, found that heart transplantation using donation after cardiac death (DCD) with normothermic regional perfusion (NRP) is feasible in the United States. Broader application of DCD heart transplantation has the potential to increase cardiac allograft availability by 20-30 percent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2021 Category: International Medicine & Public Health Source Type: news

Atrial fenestration during AVSD repair is associated with increased mortality
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, shows an association between decreased survival at five years and leaving an atrial communication at biventricular repair of unbalanced AVSD after adjusting for other known risk factors. The study sought to determine factors associated with mortality after biventricular repair of AVSD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2021 Category: International Medicine & Public Health Source Type: news

AATS Foundation scholarships shown to support success in academic surgery
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, finds that AATS Foundation fellowships support success in academic surgery career tracks. The AATS Foundation has two primary grant funding mechanisms: the AATS Foundation Scholarship and the Surgical Investigator Award. The study looked at publications, citations, NIH funding, and leadership position of awardees, among other factors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2021 Category: International Medicine & Public Health Source Type: news

Study finds up to 24 percent of esophagectomy patients can develop VTE post-operatively
(American Association for Thoracic Surgery) A new study presented today at the AATS 101st Annual Meeting, found that the percentage of patients undergoing esophagectomy for cancer who suffer Venous Thromboembolism (VTE) post-operatively is much higher than previously reported, with as many as 24 percent suffering from Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Six-month mortality for patients with VTE was 17.6 percent compared to 2.1 percent for those without. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2021 Category: International Medicine & Public Health Source Type: news

Low profile thoracic aortic endograft device reduces complications and expands patient pool
(American Association for Thoracic Surgery) Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2021 Category: International Medicine & Public Health Source Type: news

Most mitral regurgitation patients treated with TEER will require surgery if treatment fails
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, and simultaneously published in the Journal of the American College of Cardiology, finds that patients suffering from severe mitral regurgitation should be carefully screened and counselled before undergoing transcatheter edge-to-edge mitral repair (TEER). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2021 Category: International Medicine & Public Health Source Type: news

Science Saturday: Researchers explore personalized approach to anti-obesity medications
Individualized medicine initiatives mainly focus on rare diseases or cancer. Little has been attempted to individualize treatment for noncommunicable chronic diseases such as obesity -- a chronic, relapsing disease, and a primary cause of Type 2 diabetes, fatty liver disease, cardiovascular disease and cancer. There are many obesity interventions, such as diets, devices, surgery and [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 1, 2021 Category: Databases & Libraries Source Type: news

Study finds similar long-term outcomes for mechanically-ventilated COVID-19 patients
(American Association for Thoracic Surgery) A new study, presented today at the AATS 101st Annual Meeting, found that severely ill COVID-19 patients treated with ECMO did not suffer worse long-term outcomes than other mechanically-ventilated patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2021 Category: International Medicine & Public Health Source Type: news

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche's introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could ...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche's introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could ...
Source: Roche Investor Update - April 28, 2021 Category: Pharmaceuticals Source Type: news

AATS 101st Annual Meeting tip sheet
(American Association for Thoracic Surgery) The American Association for Thoracic Surgery Annual Meeting is the oldest and largest cardiothoracic surgery meeting in North America. The 101st Annual Meeting will be held virtually April 30 - May 2, 2021 (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2021 Category: International Medicine & Public Health Source Type: news

Mayo Clinic Q & amp;A podcast: Reducing rejection by reversing order of heart-liver transplant
For heart-liver transplants, the liver and heart must come from the same donor, and some patients wait years to receive both organs. Also, antibodies from the donor can increase chances of the receiving patient rejecting the heart. But Dr. Sudhir Kushwaha, a Mayo Clinic cardiovascular transplant surgeon, says when a liver transplant is also involved, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 27, 2021 Category: Databases & Libraries Source Type: news

Delaying cardiovascular surgeries due to COVID-19 has psychological effects on patients
(Michigan Medicine - University of Michigan) Postponing procedures during the pandemic sparked anxiety and fear among patients, with many concerned about dying of their conditions before getting surgery. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 19, 2021 Category: Infectious Diseases Source Type: news

Weight linked to risk of second cancer after breast cancer
Breast cancer survivors who are overweight have a higher risk of developin...Read more on AuntMinnie.comRelated Reading: Thoracic CT shows promise for monitoring health of obese patients CT-guided renal ablation is safe for treating cancer in obese patients Black women with breast cancer show high comorbidity rates Weight-loss surgery weakens teenagers' bones Use CTA to evaluate obese COVID-19 patients for PE risk (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 14, 2021 Category: Radiology Source Type: news

COVID-19 Patient Receives Lung Transplant From Living Donors
TOKYO — Doctors in Japan announced Thursday they have successfully performed the world’s first transplant of lung tissue from living donors to a patient with severe lung damage from COVID-19. The recipient, identified only as a woman from Japan’s western region of Kansai, is recovering after the nearly 11-hour operation on Wednesday, Kyoto University Hospital said in a statement. It said her husband and son, who donated parts of their lungs, are also in stable condition. The university said it was the world’s first transplant of lung tissue from living donors to a person with COVID-19 lung damage. T...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Authors: MARI YAMAGUCHI / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

AHA News: For Heart Patients, Bariatric Surgery May Lower Risk of Future Cardiovascular Problems
Title: AHA News: For Heart Patients, Bariatric Surgery May Lower Risk of Future Cardiovascular ProblemsCategory: Health NewsCreated: 4/5/2021 12:00:00 AMLast Editorial Review: 4/6/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 6, 2021 Category: Cardiology Source Type: news

AHA News: For Heart Patients, Bariatric Surgery May Lower Risk of Future Cardiovascular Problems
MONDAY, April 5, 2021 (American Heart Association News) -- Bariatric surgery can be a difficult decision for treating obesity, as patients and their doctors weigh the risks and side effects of the procedure against the benefits of the weight loss... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 5, 2021 Category: General Medicine Source Type: news

Mayo Clinic Q & amp;A podcast: Esophageal cancer is one of the deadliest cancers
Esophageal cancer occurs in the esophagus -- a long, hollow tube that runs from the throat to the stomach -- and can occur anywhere along the esophagus. Men are more likely to develop esophageal cancer than women. While treatable, esophageal cancer is rarely curable. "It's an uncommon cancer," says Dr. Shanda Blackmon, a Mayo Clinic general thoracic surgeon. [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 5, 2021 Category: Databases & Libraries Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thoracic Surgeon Raja Flores Enters NYC Mayor ’s Race
Thoracic surgeon and mesothelioma specialist Dr. Raja Flores wants to continue serving others, but in a new role as the next mayor of New York City. “Yes, I’m serious about this. Very serious,” Flores told The Mesothelioma Center at Asbestos.com Tuesday after another 14-hour workday and an evening surgery at Mount Sinai. “I want to take care of this city that has taken such good care of me.” Flores, the esteemed chairman of thoracic surgery at Mount Sinai Hospital, filed his official eligibility petition last week with the New York City Board of Elections. He listed himself as an inde...
Source: Asbestos and Mesothelioma News - March 25, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Total Knee Replacement Cost-Effective, Even With Obesity and Comorbidities Total Knee Replacement Cost-Effective, Even With Obesity and Comorbidities
Total knee replacement surgery can be a cost-effective procedure for patients with severe obesity and osteoarthritis, even when they also have comorbidities such as cardiovascular disease or type 2 diabetes, a new study suggests.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 23, 2021 Category: Orthopaedics Tags: Orthopaedics News Source Type: news

Lymph node collection kit may improve long-term survival after lung cancer surgery
(International Association for the Study of Lung Cancer) A lymph node collection kit can help surgeons attain compete resection and improve long-term survival after curative-intent lung cancer surgery, according to a study published in the Journal of Thoracic Oncology Clinical and Research Reports. The journal is published by the International Association for the Study of Lung Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2021 Category: Cancer & Oncology Source Type: news

Brendon Stiles, M.D., Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein College of Medicine
March 18, 2020—(BRONX, NY)— Leading cardiothoracic surgeon and researcher, Brendon Stiles, M.D., has been appointed chief of the division of thoracic surgery& surgical oncology in the department of cardiothoracic and vascular surgery atMontefiore Health System andAlbert Einstein College of Medicine. Dr. Stiles will also join the Einstein faculty with a senior academic appointment. Additionally, Dr. Stiles is serving as the associate director of surgical services for the surgical oncology line at the National Cancer Institute-designatedAlbert Einstein Cancer Center. (Source: Einstein News)
Source: Einstein News - March 22, 2021 Category: Universities & Medical Training Source Type: news

Some Mesothelioma Patients May Benefit from Second Radical Surgery
This study should elicit a call of hands for centers to share their experiences, to say either do it, or not do it,” Elsayed said. “Right now, you just don’t find a good number of centers doing that second operation.” Earlier Mesothelioma Surgery Studies  This most recent report focused on three smaller studies totaling 40 patients involved in a second major surgery with a curative intent for mesothelioma. In the first group of 16 patients, there was a median survival of 20.4 months after the second surgery for those with epithelial cell type, but only 7.4 months survival for those wit...
Source: Asbestos and Mesothelioma News - March 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Singapore scientists develop novel gene editor to correct disease-causing mutations
(Agency for Science, Technology and Research (A*STAR), Singapore) The Genome Institute of Singapore (GIS) has developed a CRISPR-based gene editor to correct mutations that cause genetic disorders. The C-to-G Base Editor (CGBE) by GIS advances the widely adopted CRISPR-Cas9 technology to enable molecular surgery on the human genome. This invention opens up treatment options for approximately 40 per cent of single-base substitutions associated with human diseases - including cystic fibrosis, cardiovascular diseases, musculoskeletal diseases, and neurological disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 11, 2021 Category: Biology Source Type: news

New Link Between Women with Mesothelioma and Survival Genes
Men with mesothelioma outnumber women four to one. However, numerous studies have shown that women with mesothelioma often have a survival advantage over men. Now, scientists might have a better understanding of why. Researchers have identified a gene that predicts the prognosis and treatment outcome for women with malignant pleural mesothelioma. The research took place as part of the International Mesothelioma Program at Brigham and Women’s Hospital in Boston. Dr. Assunta De Rienzo led the new study after years of research highlighting the sex-based disparity among mesothelioma patients. “The goal is ...
Source: Asbestos and Mesothelioma News - March 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news